Citi Downgrades Arcturus Therapeutics (ARCT) to Neutral
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Price: $8.14 --0%
Rating Summary:
13 Buy, 5 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 23
Rating Summary:
13 Buy, 5 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 23
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz downgraded Arcturus Therapeutics (NASDAQ: ARCT) from Buy to Neutral with a price target of $12.00.
For an analyst ratings summary and ratings history on Arcturus Therapeutics click here. For more ratings news on Arcturus Therapeutics click here.
Shares of Arcturus Therapeutics closed at $11.54 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- UBS Reiterates Neutral Rating on Intuit (INTU) as Payroll Price Increases
- Streamex Corp. (STEX) PT Lowered to $4 at Needham
Create E-mail Alert Related Categories
DowngradesRelated Entities
Citi, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
